- Home
- SDHY vs TKNO Comparison
SDHY vs TKNO Comparison
Compare SDHY & TKNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDHY
- TKNO
- Stock Information
- Founded
- SDHY 2020
- TKNO 1996
- Country
- SDHY United States
- TKNO United States
- Employees
- SDHY N/A
- TKNO N/A
- Industry
- SDHY Finance/Investors Services
- TKNO Medicinal Chemicals and Botanical Products
- Sector
- SDHY Finance
- TKNO Health Care
- Exchange
- SDHY Nasdaq
- TKNO Nasdaq
- Market Cap
- SDHY 402.7M
- TKNO 430.2M
- IPO Year
- SDHY N/A
- TKNO 2021
- Fundamental
- Price
- SDHY $16.63
- TKNO $9.49
- Analyst Decision
- SDHY
- TKNO Buy
- Analyst Count
- SDHY 0
- TKNO 2
- Target Price
- SDHY N/A
- TKNO $5.00
- AVG Volume (30 Days)
- SDHY 94.0K
- TKNO 228.0K
- Earning Date
- SDHY 01-01-0001
- TKNO 03-10-2025
- Dividend Yield
- SDHY 8.46%
- TKNO N/A
- EPS Growth
- SDHY N/A
- TKNO N/A
- EPS
- SDHY 1.07
- TKNO N/A
- Revenue
- SDHY N/A
- TKNO $36,347,000.00
- Revenue This Year
- SDHY N/A
- TKNO $3.47
- Revenue Next Year
- SDHY N/A
- TKNO $12.07
- P/E Ratio
- SDHY $14.31
- TKNO N/A
- Revenue Growth
- SDHY N/A
- TKNO N/A
- 52 Week Low
- SDHY $13.93
- TKNO $1.16
- 52 Week High
- SDHY $15.50
- TKNO $10.37
- Technical
- Relative Strength Index (RSI)
- SDHY 61.59
- TKNO 56.46
- Support Level
- SDHY $16.42
- TKNO $7.74
- Resistance Level
- SDHY $16.65
- TKNO $9.86
- Average True Range (ATR)
- SDHY 0.12
- TKNO 0.85
- MACD
- SDHY 0.02
- TKNO 0.07
- Stochastic Oscillator
- SDHY 83.86
- TKNO 63.66
About SDHY PGIM Short Duration High Yield Opportunities Fund
PGIM Short Duration High Yield Opportunities is a closed-end management investment company. The fund's investment objective is to provide total return, through a combination of current income and capital appreciation. Its seeks to achieve its objective by investing in a diversified portfolio of high yield fixed income instruments.
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. It derives maximum revenue from United States.